Premium
Absolute bioavailability and pharmacokinetics of medifoxamine in healthy humans.
Author(s) -
Saleh S,
Johnston A,
Turner P
Publication year - 1990
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1990.tb03823.x
Subject(s) - bioavailability , pharmacokinetics , oral administration , absorption (acoustics) , pharmacology , medicine , limiting , antidepressant , venous blood , oral dose , mechanical engineering , physics , acoustics , hippocampus , engineering
Medifoxamine is a new monoamine re‐uptake inhibiting antidepressant drug. Twelve volunteers received 100 mg by i.v. infusion over 15 min and 500 mg by mouth fasting. The treatments were given 1 week apart in a randomised cross‐over design. Venous blood samples (10 ml) were taken at intervals for 24 h for h.p.l.c. measurement of serum medifoxamine. A biexponential decline of serum medifoxamine concentration was observed after intravenous administration in all subjects and similar terminal elimination half‐lives were observed following both routes, indicating that oral absorption is not rate‐limiting. The absolute bioavailability of oral medifoxamine was 21%.